ENTA.O (ENTA.O) News
Follow ENTA.O (ENTA.O) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Enanta to present Phase 2 trial data for RSV drug candidate zelicapavir at IDWeek 2026
Enanta Pharmaceuticals flagged new Phase 2 results for RSV drug candidate zelicapavir, scheduled for presentation at IDWeek 2026. Trial data indicate faster symptom resolution, fewer hospitalizations, lower viral burden
NEWS | Oct 13, 2026, 11:02 AM UTC
H
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once — Daily, N — Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
For best results when printing this announcement, please click on link below: Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respirat
NEWS | Oct 13, 2026, 11:00 AM UTC